Breast Cancer DetectionNCT07056686
Early Detection of Breast Cancer Among Syrian Women
An observational study of Breast Cancer Detection, run by Al-Hawash Private University at 1 site in Syria.
Trial summary
The goal of this observational study is to evaluate breast cancer awareness, screening practices, and barriers to early detection among women in the middle region of Syria. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 18 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer Detection
- What is being tested?
- Mammogram
- How many people
- 1,000 participants
- Where
- 1 siteSyria
- Study dates
- 17 May 2025to 30 Jul 2027
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Women in the middle range between 118 and 65 years old
Women aged 18 and older residing in Syria's middle region.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Early Detection of Breast Cancer Among Women in the Middle Region of Syria
The goal of this observational study is to evaluate breast cancer awareness, screening practices, and barriers to early detection among women in the middle region of Syria. The main questions it aims to answer are:
- What is the level of awareness among women in this region regarding breast cancer symptoms and risk factors?
- How do women practice breast self-examination and professional screenings?
- What barriers prevent women from seeking early detection and treatment?
Participants will complete a survey assessing their knowledge, behaviors, and challenges related to breast cancer screening. The findings will inform public health interventions to improve awareness and early detection practices.
- Conditions
- Breast Cancer Detection
- Being tested
- Mammogram
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MammogramDiagnostic test
Each patient will undergo a mammogram, which is used to detect early signs of cancer, such as tumors or calcifications, before symptoms appear.
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with early signs of breast cancer
Measured: From Participant enrolment to the end of the study: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study start17 May 2025
- Primary completion31 May 2025
- Study completion30 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast Cancer DetectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Al-Hawash Private University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07056686
- Sponsor's protocol ID
- 01-05-2025
- Status last verified
- Oct 2026
- First submitted
- 29 Jun 2025
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Detection of Breast Cancer Among Women in the Middle Region of Syria
- ClinicalTrials.gov ID
- NCT07056686
- Acronym / sponsor ID
- 01-05-2025
- Conditions
- Breast Cancer Detection
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Al-Hawash Private UniversityUniversity, hospital or other
- Study start
- 17 May 2025 (actual)
- Primary completion
- 31 May 2025 (actual)
- Study completion
- 30 Jul 2027 (estimated)
- First posted
- 9 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate breast cancer awareness, screening practices, and barriers to early detection among women in the middle region of Syria. The main questions it aims to answer are:
- What is the level of awareness among women in this region regarding breast cancer symptoms and risk factors?
- How do women practice breast self-examination and professional screenings?
- What barriers prevent women from seeking early detection and treatment?
Participants will complete a survey assessing their knowledge, behaviors, and challenges related to breast cancer screening. The findings will inform public health interventions to improve awareness and early detection practices.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Women in the middle range between 118 and 65 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MammogramEach patient will undergo a mammogram, which is used to detect early signs of cancer, such as tumors or calcifications, before symptoms appear. | Diagnostic test | – |
Primary outcome
Number of Participants with early signs of breast cancer
Time frame: From Participant enrolment to the end of the study: 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer Detection
Not yet recruiting
Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of Estrogen Receptor 1 (ESR1) Mutations in (Human Epidermal Growth Factor Receptor) HR+/HER2- Metastatic Breast Cancer (MBC)
Breast Cancer, Metastatic Breast Cancer
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingObservational study
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Brain Cancer, Breast Cancer
RecruitingObservational study
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
Not yet recruitingPhase 4
FES PET/MRI for Occult Disease in Lobular Breast Cancer
Lobular Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer Detection, run by Al-Hawash Private University at 1 site in Syria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with early signs of breast cancer (time frame: From Participant enrolment to the end of the study: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.